Neovascularization is crucial to lung development and is mediated through a variety of angiogenic and anti-angiogenic factors. Herein, we show that excess Endothelial Monocyte Activating Polypeptide (EMAP) II, an anti-angiogenic protein, not only inhibits fetal lung neovascularization, but also signi®cantly alters airway epithelial morphogenesis. In a murine allograft model of lung neovascularization and morphogenesis, embryonic lungs transplanted under the skin of immunocompromised mice receiving intraperitoneal EMAP II, had a 56% reduction in vessel density (P , 0:0001) compared to control. EMAP II treated lung transplants also exhibited a marked alteration in lung morphogenesis, including lack of type II alveolar cell formation, determined by markedly decreased expression of surfactant protein C, and increased apoptosis. In contrast, lung implants in animals receiving an EMAP II blocking antibody had an increase in vessel density of 50% (P , 0:0001) and increased expression of surfactant protein C mRNA in distal epithelium. These studies demonstrate that EMAP II negatively modulates lung neovascularization as well as leading to the arrest of lung airway epithelial morphogenesis and apoptosis. q
Introduction
Lung development is governed by instructive and permissive interactions between the epithelium and the mesenchyme. Lung epithelial branching and differentiation is dependent on signals from the mesenchyme and similarly branching and differentiation of the vasculature within the mesenchyme is maintained through interactions with the epithelium (Masters, 1976; Wessells, 1977; Gebb and Shannon, 2000) . Epithelial branching morphogenesis is paralleled spatially and temporally by vascularization of the developing lung and collectively these observations suggest that lung morphogenesis critically depends on neovascularization.
Factors promoting growth and differentiation of the pulmonary vasculature have been identi®ed, however these positive stimuli are balanced by factors that oppose vascularization and that to date remain largely unidenti®ed. A candidate negative modulator, Endothelial Monocyte Activating Polypeptide (EMAP) II (Kao et al., 1992 (Kao et al., , 1993 (Kao et al., , 1994 ) is a potent tumor anti-angiogenic factor (Schwarz et al., 1999b) and its temporo-spatial localization in the developing lung suggests a potential role as a negative regulator of lung neovascularization (Schwarz et al., 1999a) .
To investigate the role of EMAP II in lung development, neovascularization and epithelial maturation were assessed in the presence of either exogenous EMAP II protein or a neutralizing antibody in an embryonic lung allograft model. Subcutaneous lung allografts in mice receiving exogenous EMAP II protein showed a marked decrease in vessel formation and an increase in apoptosis as compared to control. Conversely, an EMAP II blocking antibody in the lung allograft model markedly increased vessel formation. Furthermore, lung allografts exposed to EMAP II protein were markedly hypoplastic and airway epithelial morphogenesis appeared to be arrested at the canalicular stage, marked by cuboidal, glycogen-rich epithelial cells that did not express SP-C. In contrast, fetal lung allografts receiving EMAP II blocking antibody had increased cellularity in the proximal and distal airway structures and the distal alveolar cell expressed a greater amount of SP-C mRNA expression. These studies demonstrate that EMAP II inhibits lung neovascularization and epithelial morphogenesis. This suggest that neovascularization plays an important role in lung development.
Results

Puri®cation of recombinant EMAP II
In order to determine the function of EMAP II in the developing lung, we developed an easy and reproducible system for producing recombinant EMAP II. A PET28a 6X His-tag system was used to quickly and ef®ciently isolate mature rEMAP II under native conditions. Recombinant (r) EMAp II was expressed in E. coli, induced with 1±4 mM IPTG and the E. coli pelleted after 3±4 h of induction. The puri®ed, recombinant mature form of EMAP II had MR A Ê 23 kDa (with the 6X His-tag) on both reduced and non-reduced SDS-PAGE. Activity of rEMAP II, measured by induction of TNF-a and monocyte migration (Kao et al., 1994) , was found to be analogous to that previously observed with meth A-derived EMAP II. LPS levels were ,15 pg/ml as measured with a LAL kit (Biowhittaker QCL-1000). Heat-treated EMAP II was inactive in these assays. The peptide antibody generated in a rabbit, is speci®c to EMAP II, identi®ed by producing a single band on Western analysis that is blocked after being incubated with excess EMAP II (data not shown).
EMAP II inhibition of fetal lung vascular development
To better de®ne EMAP II's role in embryonic lung neovascularization, murine lungs obtained at gestational age 14.5 days, were implanted subcutaneously into nude mice. Mice then received either vehicle, rEMAP II protein (1 mg/day), EMAP II blocking antibody (25 or 50 mg)IP every day or rabbit IgG every 3 days for 14 days. Lung transplants were then excised and evaluated for vascular and structural development using PECAM-1 and hematoxylin and eosin staining, respectively. Compared to lung allografts implanted in mice treated with vehicle alone, implants in mice receiving the anti-angiogenic protein EMAP II exhibited a striking 56% decrease in capillary numbers (Fig. 1B,D) (P , 0:0001) as compared to control (Fig.  1A) . In contrast, animals receiving blocking antibody to EMAP II had a signi®cant dose dependent increase of 50% (P , 0:0001) in vessel counts per HPF (Fig. 1C,E) . Consistent with these histologic ®ndings, mRNA harvested from lung allografts of animals treated with rEMAP II, lane 4 in Fig. 1F , demonstrated a reduction in PECAM-1 and Tie-2 by RT-PCR compared to control in lane 1 in Fig.   1F ). Conversely, an increase in PECAM-1 and Tie-2 PCR products, were obtained from allografts in animals treated with the blocking EMAP II antibody, lane 3 (Fig. 1F ) as compared to non-speci®c rabbit IgG in lane 2. Negative controls for PCR ampli®cation of the PECAM-1 and Tie-2 transcripts, without RT, demonstrated no speci®c PCR product in each reaction (data not shown).
EMAP II inhibits epithelial maturation
We observed that EMAP II protein inhibition of neovascularization was accompanied by signi®cant structural changes in the lung allografts and thus we postulated that pulmonary vascularization and airway epithelial cell differentiation are interdependent processes. After administration of rEMAP II, histologic analysis of lung allografts in these mice showed a marked inhibition of airway epithelial morphogenesis demonstrated by a lack of well-de®ned bronchi ( Fig. 2D and inset) . The epithelium present was markedly attenuated and structurally more consistent with distal epithelium (Fig. 2D±F ) as compared to vehicle treated animals ( Fig. 2A±C ). In addition, in lung allografts in mice treated with EMAP II, the alveolar epithelial cells appeared dysplastic (Fig. 2E,F) and there was an apparent¯attening of the airway epithelial cells (Fig. 2D, inset ) as compared to the airway epithelium in those transplants in mice receiving vehicle alone ( Fig. 2A, inset) . To discern whether morphologic progression actually occurred, we assessed the allografts for markers of distal lung morphogenesis. Lung allografts in mice receiving vehicle alone underwent type II alveolar cell differentiation as marked by cellular expression of SP-C mRNA (Fig. 3A,B) . In contrast, lung allografts in animals receiving EMAP II had a marked reduction in SP-C expression throughout the entire transplanted lung, even in the most peripheral airways (Fig. 3C,D) . Further supporting our ®ndings, animals receiving blocking EMAP II antibody had a strikingly increased number of epithelial cells that expressed SP-C, with essentially every distal epithelial cell synthesizing SP-C (Fig. 3E,F) . Therefore, excess EMAP II protein lead to profound inhibition of peripheral lung epithelial morphogenesis and differentiation and the opposite was true in allografts treated with EMAP II antibody which appeared to have increased distal structures.
Consistent with the in situ hybridization ®ndings, mRNA harvested from lung allografts of animals treated with rEMAP II, lane 4 Fig. 3G , demonstrated a reduction in SP-C by RT-PCR compared to controls, lane 1 Fig. 3G . In contrast, animals treated with the blocking EMAP II antibody exhibited an increase in the SP-C amplicon con®rming the in situ results in lane 3 (Fig. 3G ) as compared to nonspeci®c rabbit IgG in lane 2 Fig. 3G (RNA was isolated from pooled lung allografts and performed on three separate occasions). Negative controls for PCR ampli®cation of the SP-C without RT, demonstrated no speci®c PCR product in each reaction (data not shown).
To further characterize the epithelial populations observed in the allografts, glycogen production was assessed in the lung allografts. Allografts obtained from mice treated with rEMAP II demonstrated excess glycogen (denoted by the magenta color) (Fig. 4D±F ) compared to vehicle alone ( Fig. 4A±C) , further supporting the concept that EMAP II inhibited epithelial differentiation.
To investigate whether programmed cell death plays a role in the lung hypoplasia induced by EMAP II, the TUNEL assay was performed on histologic sections. A basal level of apoptosis is on going in vehicle treated allografts secondary to the revascularization process of the implantation (Fig. 5A ). However, a marked increase in apoptosis is evident in allografts treated with EMAP II protein (Fig. 5B , high power inset, arrows indicating apoptotic cells). This indicates that the acellularity and hypoplasia observed in EMAP II protein treated allografts may be due in part to the marked increase in apoptosis.
Discussion
Herein, we ascribe key roles for the anti-angiogenic protein EMAP II in fetal lung morphogenesis. We observed that EMAP II decreased vessel density in developing lung allografts while an EMAP II blocking antibody increased vessel density. Furthermore, in lung allografts exposed to EMAP II, airway epithelial morphogenesis appeared to be arrested, marked by cuboidal, glycogen-rich airway epithelial cells that did not express SP-C, whereas in lungs allografted into mice that received an EMAP II blocking Fig. 1 . EMAP II inhibits fetal lung vascular development. Fetal lung allografts treated 14 days with rEMAP II protein, EMAP II antibody, or vehicle (PBS or rabbit IgG respectively) were evaluated for vessel formation using the PECAM-1 antibody. Diffuse PECAM-1 immunostaining was found in the mesenchyme surrounding the branching epithelium in vehicle treated allografts (A, typical vessels indicated by arrows). In contrast, few PECAM-1 positive structures were found in the allografts treated with rEMAP II (B). Vessel counts demonstrated a 56% reduction in neovascularization in animals receiving rEMAP II compared to control (D, typical vessels indicated by arrows) (P , 0:0001). (n 20 implants/group performed on four separate occasions). Conversely, EMAP II antibody induced a 50% increase (P , 0:0001) in vessel number (C, typical vessels indicated by arrows, E) (n 10/group performed on three separate occasions). Changes observed immunohistochemically were con®rmed by RT-PCR. REMAP II protein decreased PECAM-1 and Tie-2 mRNA (F, lane 4) whereas EMAP II antibody increased expression of PECAM-1 and Tie-2 (F, lane 3). Vehicle (PBS) and IgG were used as control comparisons for EMAP II protein and EMAP II antibody treatments respectively. RT-PCR results were normalized using the b-actin as an internal control (RNA was isolated from pooled lung allografts and performed on three separate occasions). Bar, 250 mm.
antibody, almost every distal alveolar cell expressed a greater amount of SP-C. Therefore, our ®ndings suggest that EMAP II plays a dual inhibitory role in both lung vascularization and lung epithelial morphogenesis.
Lung neovascularization
Vasculogenesis and angiogenesis, the two forces driving neovascularization (Poole and Cof®n, 1989; Cof®n et al., 1991) , depend on epithelial-mesenchymal interactions to guide vessel formation. Formation of the ®rst primitive vasculature during vasculogenesis is mediated by transdifferentiation of mesodermal cells into endothelial cells which organize and condense into vascular structures. In contrast, angiogenesis is characterized by the extension of previously formed vessels into undervascularized regions. The latter process involves endothelial cell proliferation and vessel sprouting, leading to formation of new vascular structures.
Our understanding of the processes that positively regulate vessel formation in the fetus (Yamaguchi et al., 1993; Drake and Little, 1995; Flamme et al., 1995; Gebb and Shannon, 1998 ) is improving. However, little is known regarding those factors that negatively modulate vessel formation. We postulated that anti-angiogenic proteins might play a vital role modulating vascular growth during lung development, by providing a negative balance to the positive angiogenic factors. The role of EMAP II, an antiangiogenic protein, was evaluated in lung neovascularization because prior studies indicated that its temporo-spatial expression was consistent with that of a negative modulator of pulmonary vascularization (Schwarz et al., 1999a) .
We employed a lung allograft model of lung neovascularization and morphogenesis to determine if EMAP II had an impact on lung vascular growth because this model provided characteristic vessel development. Previously we have observed in this lung model, the vessel counts preimplantation are 25^1.4 SE vessels per high powered ®eld (HPF), decline 3 days following implantation to 17^0.9 SE HPF, return to baseline by 7 days, and reach 62^2.8 SE vessels HPF by 14 days of implantation (Schwarz et al., 2000) . Based on this, we used this model to compare vessel development in protein and antibody treated lungs. We observed that lung neovascularization in allografts transplanted into animals that received EMAP II protein (22^1.7 SE HPF) was markedly reduced, barely returning to baseline. In contrast, allografts in mice receiving EMAP II antibody had a dose dependent increase in vessel counts (73^1.4 and 83^1.8 SE HPF). There are two mechanisms that could account for EMAP II's inhibition of neovas- cularization: (1) EMAP II has a direct inhibitory effect on existing endothelial cells either by inhibiting angiogenesis or the sprouting of existing vessels; or (2) EMAP II targets the pluripotent mesenchymal cells thus inhibiting vessel formation in situ.
Little is currently known regarding the role of anti-angiogenic proteins in fetal development in general. However, we know that excess amounts of a positive modulator leads to aberrant vessel formation demonstrating that there is a balance between positive and negative regulators and disruption of this balance through the delivery of exogenous VEGF, leads to aberrant vessel formation (Drake et al., 1998) . Further, studies have shown that thalidomide induced limb defects are secondary to an inhibition of blood vessel growth in the developing fetus (D'Amato et al., 1994) .
Lung morphogenesis
Lungs treated with EMAP II display a decreased vessel density and a profound disruption of morphologic development. Our observations indicated that the delivery of excess EMAP II, during the initiation of the vascular stage, not only negatively modulated vessel formation, but inhibition of vascularization at this crucial transitional period may also have hindered airway epithelial cell differentiation and lung morphogenesis. In the control allografts, SP-C expression is localized within the distal epithelial elements of bronchial tubules prior to implantation (14.5 dpc). Seven days following implantation, SP-C expression is more abundant within the progressive respiratory duct extensions, and the initiation of type II epithelial cell differentiation. By 14 days following implantation, there is SP-C expression in alveolar type structures implicating distal differentiation. In addition there is an increase in CC10 expression in the proximal airways (data not shown). In contrast, allografts exposed to excess EMAP II protein lacked SP-C mRNA expression, consistent with an inhibition of airway epithelial differentiation. Furthermore, SP-C expression was markedly increased in allografts implanted in mice that received EMAP II antibody. During the canalicular or vascular stage, the lung is canalized with capillaries. This is associated with¯attening of the cuboidal glycogen-rich peripheral epithelial precursor cells, so that a thin air-blood interface is formed (Burri, 1997) . This stage of transition is pivotal in the normal, linked progression of lung epithelial morphogenesis and neovascular development. The lack of SP-C expression in the epithelium and the presence of a glycogen rich state in all the identi®able airway epithelium indicates that there (A,B) ; 500 mm insets of (B).
was a disturbance in this transition. In addition, we noted an increase in apoptosis in allografts of mice receiving EMAP II, implying that EMAP II either has a direct apoptotic effect on the lung airway epithelial cells or that it is a secondary affect of decreased neovascularization. Thus, based on our results, EMAP II interfered with lung neovascularization and this lead to inhibition of lung development or a regression in lung differentiation.
Emerging evidence indicates that lung morphogenesis is critically dependent on lung neovascularization, and that disrupted vascular formation leads to gross abnormalities of lung morphology. Zeng et al. (1998) have shown that in mice overexpressing VEGF transgene using a lung speci®c SP-C promoter, there are marked alterations in vasculature and morphogenesis that are con®ned to the lungs. The lungs demonstrated abnormalities in morphogenesis consisting of increased growth of the pulmonary blood vessels, disrupted branching morphogenesis of the lung and inhibition of type I cell differentiation (Zeng et al., 1998) . In contrast, when there is an inhibition of transforming growth factor (TGF) b1, a gene associated with structural maturation, mice exhibit vascular malformations (Dickson et al., 1995) . Rescue of this fetal lethal phenotype using a lung speci®c inhibition of TGF b1 through a SP-C promotor, indicates that concomitant with vascular malformations, there is an arrest of lung sacculation and epithelial cell differentiation (Zhou et al., 1996) . EMAP II's inhibition of neovascularization and the progression of normal lung epithelial morphogenesis in conjunction with these studies suggest that there is a direct relationship between lung neovascularization and normal lung morphologic development.
In summary, we have shown that excess EMAP II markedly inhibits lung neovascularization. Exogenous EMAP II interferes with normal vessel formation within the fetal lung and this is associated with an apparent arrest of lung airway epithelial cell differentiation. Thus, these studies suggest that EMAP II negatively regulates lung morphogenesis. Whether EMAP II has a direct effect on the dividing airway epithelium, or the endodermally derived epithelium and elucidation of its mechanism of action within the lung and target cell population will be the focus of subsequent studies.
Experimental procedures
Synthesis of recombinant (r) EMAP II from E. coli and generation of a peptide antibody
The cDNA of mature human EMAP II was cloned from RT-PCR products of U937 cells total RNA based on primers obtained from gene bank (accession #10119) into TA vector (Invitrogen). Con®rmation of the clones was provided by sequence analysis, after which the cDNA was inserted into PET28a, 6 X his-tag containing plasmid. E. coli (DE 3 ) underwent transformation with the EMAP II/PET28a plasmid and were induced with 1±4 mM IPTG. After 3-4 h of induction, the cells were pelleted, lysed and the EMAP II protein was puri®ed through the use of a nickel column as per protocol (Qiagen) with all procedures performed at 48C. Brie¯y, pelleted cells were lysed with 50 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, and 10 mM imidazole in the presence of lysozyme of 1 mg/ml. Following sonication, cellular debris are removed by centrifugation prior to being loaded on the Ni-NTA slurry. Following washing of the column, rEMAP II is eluted off with 50 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, and 250 mM imidazole. Puri®ed rEMAP II is dialyzed at 48C against PBS three times prior to being aliquoted and frozen at 2808C.
A peptide sequence of 13 amino acid residues located within a homologous region of the human and murine forms of mature EMAP II were used to generate an antibody. This peptide was synthesized and the antibody produced by Zymed Laboratories Inc. As per protocol and is used for immunohistochemistry and western blotting. The antibody is speci®c to EMAP II identi®ed by producing a single band on a western blot that is blocked after being incubated with excess EMAP II (data not shown).
Allograft lung transplant model
Timed pregnant Swiss Webster mice at gestational day 12 (based on appearance of vaginal plug day 0) were obtained, housed, and handled according to a protocol approved by the animal care committee at CHLARI (Children's Hospital of Los Angeles Research Institute). On day 14.5 dams were sacri®ced and the embryo removed (Schwarz et al., 2000) . The lungs and heart were withdrawn as a block microdissection and placed in ice cold PBS. The heart was then removed and the lung was placed on top of a 0.80 mM Millipore ®lter disk (Millipore) and implanted into a dorsal skinfold chamber of a nude mouse using sterile technique. The skin was closed with skin staples. A sibling lung was used for histological analysis and comparison to the implanted lung. Nude mice were then injected intraperitoneal by (IP) on a daily basis with either vehicle (phosphate buffered saline, PBS and albumin), EMAP II (1 mg/day) (dosing based on 125 I EMAP II clearance studies, (Schwarz et al., 1999b) , rabbit IgG or EMAP II antibody (25 or 50 mg/every 3 days) (dosing based on 125 I EMAP II antibody labeled clearance studies, data not published).
RT-PCR of lung transplants
Following 14 days, lung allografts were removed from mice that had been treated with rEMAP II, antibody to EMAP II, or vehicle, separated from the carrier mouse skin, lung allografts were pooled, total RNA was extracted by RNA Inc., Friendswood, TX) and the RNA of the transplanted lungs were reverse transcribed by superscript II RNase H ± reverse transcriptase 4.5. Digoxigenin RNA probe labeling by in vitro transcription DNA of the SP-C subclone, in good orientation for in vitro transcription of antisense RNA by T7 RNA polymerase, was linearized by Hind III digestion and used as a template for probe labeling. Antisense RNA probe labeling with digoxigenin-UTP by in vitro transcription with T7 RNA polymerase was performed as per manufactures instructions (DIG RNA labeling kit, Boehringer Mannheim, Indianapolis, IN).
4.6. RNA in situ hybridization (RISH) using DIG-labeled cRNA probes
Murine embryo control lung day 14 g.a. and murine transplants, days 14 1 3.5, 14 1 7, 14 1 10.5, and 14 1 14 g.a. were obtained for in situ hybridization. The Dig RNA probe anti-sense and sense (control) were made using the Dig RNA labeling Kit (SP6/T7) from Boehringer Mannheim (Indianapolis, IN) . RISH was performed on 5-mm paraf®n embedded material sections according to non-radioactive in situ hybridization application manual (Boehringer Mannheim, Indianapolis, IN). Using DEPC treated equipment and solutions, paraf®n embedded specimens underwent sectioning, rehydration and incubation in a prewarmed 5 mg/ml proteinase K solution. Slides were then reimmersed in 4% PFA, treated with a 0.25% acetic anhydride and dehydrated. Sections were exposed to a hybridization solution containing 50% formamide, 10% dextran sulfate, 1 mg/ml tRNA, 1£ Denhardt's solution, 4£ SSC, 50 mM Tris and 5 mM EDTA that contained 150±300 ng/ml of dig-labeled RNA probe at 508C overnight. Slides were washed at 558C in 2£ SSC/50% formamide, 1£ SSC and 0.1 SSC for 30 min prior to being incubated with RNase A (20 mg/ml) for 30 min at 378C. After being rinsed with 2£ SSC and Dig Nucleic Acid detection was accomplished using the Genius 3 kit from Boehringer Mannheim. Brie¯y, slides were incubated in 0.1 M Maleic acid/0.15 M NaCl (pH 7.5) for 5 min afterwhich they underwent blocking in a 1% block reagent. Following blocking, slides were incubated with anti-Dig-AP conjugate at 48C overnight, rinsed, and incubated with a dilute NBT / BCIP solution for 3 h at room temperature. Slides then underwent counterstaining with a 0.02% fast green solution for 2 min, rinsed in water, air dried and mounted. Hybridization with sense probe or without probe was performed as negative control and they always showed no signals. All sections were examined and photographed under light microscopy.
Histologic and immunohistochemistry analysis of the murine lung transplants
Following 14 days, lung allografts were removed from mice that had been treated with rEMAP II, blocking antibody to EMAP II, or vehicle, separated from the carrier mouse skin, ®xed in 4% paraformaldehyde, dehydrated, and paraf®n embedded (during all procedures, DEPC water and precaution against RNAses were taken). Fixed tissue was sectioned at 5 micron intervals. The lung trans-plants then underwent H & E staining for structural analysis. For immunolocalization of PECAM-1 antigens (Pharmigen, San Diego, CA), we employed a rat anti-murine PECAM-1 antibody (4 mg/ml). Tissues were deparaf®nized and underwent peroxide quenching. Using a histostain kit from Zymed (San Francisco, CA), after blocking, the sections were exposed to the primary antibody overnight at 48C. Sections were then incubated with secondary biotinylated antibody as per the manufacturer's protocol. A brief incubation with the Streptavidin-HRP conjugate system (Zymed) was followed by development using the chromogen substrate aminoethylcarbazole. Periodic Acid Schiff (PAS) stain was performed, using a kit from Sigma (St. Louis, MO) according to the manufacturer's instructions.
Differences between lung vessel formation were analyzed using PECAM-1 immunohistochemistry to identify the vasculature. Vessel counts were performed in similar regions and the vascular hot spots within lung allografts per high powered ®eld (HPF) (Vermeulen et al., 1996) . In addition, branched vessels were noted as one vessel, and the vessel counts re¯ect the combined total of capillary and larger vessels (n 20 implants/group for EMAP II and vehicle performed on four separate occasions and n 10/ group for EMAP II antibody and non-speci®c rabbit IgG performed on three separate occasions).
TUNEL analysis of fetal lung allografts
The spatial induction of apoptosis was analyzed in lung allografts using the In Situ Death Detection Kit from Boehringer Mannheim. In brief, lung allografts were ®xed in 4% paraformaldehyde, dehydrated and paraf®n embedded. Five micron sections were cut, rehydrated and prior to exposure to the TUNEL reaction (containing terminal deoxynucleotidyl transferase and a nucleotide mixture in a reaction buffer). Apoptotic cells were revealed using alkaline phosphatase and observed under light microscopy.
Statistics
Statistical analysis was performed using Student's t-test on the computer program Statview.
